I'm LongbridgeAI, I can summarize articles.Moderna completed a $3.0 billion private offering of zero-coupon convertible senior notes due March 2032, with net proceeds of approximately $2.96 billion to support general corporate purposes. To mitigate potential dilution from conversions, the company entered into capped call transactions with an initial cap of $392.62 per share, costing about $328.8 million.
Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due March 1, 2032 and executed the related indenture. The notes, initially convertible at $210.58 per share, provide flexibility for settlement in cash, stock, or a combination. To mitigate dilution from potential conversions, Moderna also entered into capped call transactions with an initial cap of approximately $392.62 per share, paying about $328.8 million for the protection. Net proceeds of roughly $2.96 billion will support general corporate purposes, including growth in oncology and potential debt repayment.
Agreement 1: Moderna Completes $3.0 Billion 0.00% Convertible Notes Due 2032; Indenture Executed
- Agreement type: Indenture for 0.00% Convertible Senior Notes due 2032
- Counterparty: U.S. Bank Trust Company
- Signed / Effective: Sep 01 2026 / same
- Duration / Termination: Through Mar 01 2032
- Reason: Raise capital and enhance financial flexibility
Agreement 2: Moderna Executes Capped Calls to Limit Dilution on 2032 Converts; Cap Set at $392.62
- Agreement type: Capped call confirmations on 2032 convertible notes
- Counterparty: Certain financial institutions
- Signed / Effective: Aug 27 2026 / same
- Duration / Termination: Through Mar 01 2032
- Reason: Reduce potential dilution from note conversions
Original SEC Filing: Moderna, Inc. [ MRNA ] - 8-K - Sep. 01, 2026